Moderna and Super Micro have topped the S&P 500 short-interest list as investors bet against their uncertain outlooks. Moderna continues to struggle post-Covid Pandemic with weak fundamentals and no new blockbuster drugs. While, Super Micro faces AI-bubble fears and past compliance issues. Analysts see more upside in Super Micro, but retail sentiment remains cautious toward both stocks.